Ikena Oncology to Participate in September 2022 Investor Conferences
September 06, 2022 07:30 ET
|
Ikena Oncology, Inc.
BOSTON, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that...
Ikena Oncology Reports Second Quarter 2022 Financial Results and Provides a Corporate Update
August 11, 2022 07:30 ET
|
Ikena Oncology, Inc.
BOSTON, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced...
Ikena Oncology to Participate in the William Blair Biotech Focus Conference 2022
July 06, 2022 07:00 ET
|
Ikena Oncology, Inc.
BOSTON, July 06, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that...
Ikena Oncology Receives FDA Fast Track Designation for Novel TEAD Inhibitor IK-930 to Treat Unresectable NF2-Deficient Mesothelioma
June 22, 2022 07:00 ET
|
Ikena Oncology, Inc.
BOSTON, June 22, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that...
Ikena Oncology to Participate in Spring 2022 Investor Conferences
May 18, 2022 07:00 ET
|
Ikena Oncology, Inc.
BOSTON, May 18, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that...
Ikena Oncology Reports First Quarter 2022 Financial Results and Provides a Corporate Update
May 12, 2022 07:00 ET
|
Ikena Oncology, Inc.
IK-175 clinical trial combination expansion cohort in patients with urothelial carcinoma advanced to Stage 2 based on tolerability and preliminary anti-tumor activity First patients dosed in our...
Ikena Oncology and Vall d’Hebron Institute of Oncology Announce Research & Development Collaboration
May 02, 2022 07:00 ET
|
Ikena Oncology, Inc.
BOSTON, May 02, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA), a targeted oncology company forging new territory in patient-directed cancer treatment, and the Vall d’Hebron Institute...
Ikena Oncology to Present at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting
April 28, 2022 07:00 ET
|
Ikena Oncology, Inc.
BOSTON, April 28, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that...
Ikena Appoints Jotin Marango, M.D., Ph.D., as Chief Financial Officer and Head of Corporate Development
April 13, 2022 07:00 ET
|
Ikena Oncology, Inc.
BOSTON, April 13, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced the...
Ikena Oncology to Present Preclinical Findings on IK-930, a Novel TEAD Inhibitor at the 2022 American Association for Cancer Research (AACR) Annual Meeting
March 07, 2022 16:30 ET
|
Ikena Oncology, Inc.
BOSTON, March 07, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA), a targeted oncology company navigating new territory in patient-directed cancer treatment, today announced that it...